Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 2/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
| ▸ | LDHB | P07195 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663113 | 0.96 | LMNA (0.36) | LMNAALDH1A1OR51E2TDP1ACHE | |
| Ammonia Solution, Strong SCHEMBL10618980 | 0.96 | LMNA (0.36) | LMNAALDH1A1OR51E2TDP1ACHE | |
| SCHEMBL3359099 | 0.87 | ACHE (0.35) | ACHELDHALDHB | |
| SCHEMBL30671765 | 0.84 | ACHE (0.33) | ACHELDHALDHB | |
| SCHEMBL228466 | 0.82 | — | — | |
| SCHEMBL6743655 | 0.82 | — | — | |
| SCHEMBL28768793 | 0.79 | — | — | |
| Ammonia Solution, Strong SCHEMBL17223995 | 0.78 | — | — | |
| SCHEMBL10425379 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL453946 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150328230-A1 | CLEARANCE OF AMYLOID BETA | SYNAPTEC DEVELOPMENT LLC (US) | 2015-11-19 | — | — | US | claimed |
| JP-56040658-A | — | — | None | — | — | JP | disclosed |
| CN-117466939-A | Long-acting prodrug derivative for controlling in-vivo drug release | 烟台药物研究所 | 2024-01-30 | — | — | CN | disclosed |
| US-11812741-B2 | Method for producing a biocide | A.Y. LABORATORIES LTD. (IL) | 2023-11-14 | — | — | US | disclosed |
| EP-3665168-A1 | PROCESS TO PREPARE PROPYLENE AMINES AND PROPYLENE AMINE DERIVATIVES | Nouryon Chemicals International B.V. (NL) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019030197-A1 | PROCESS TO PREPARE PROPYLENE AMINES AND PROPYLENE AMINE DERIVATIVES | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2019-02-14 | — | — | WO | disclosed |
| US-9272242-B2 | High cyclic capacity amines for high efficiency CO2 scrubbing processes | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-20140030177-A1 | HIGH CYCLIC CAPACITY AMINES FOR HIGH EFFICIENCY CO2 SCRUBBING PROCESSES | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| CN-102177213-A | Adhesive laminate | ASAHI GLASS CO LTD | 2011-09-07 | — | — | CN | disclosed |
| EP-2115084-A2 | METHOD FOR PREPARING POLYHYDROXY-URETHANES | Rhodia Opérations (FR) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008107568-A2 | METHOD FOR PREPARING POLYHYDROXY-URETHANES | RHODIA OPERATIONS (FR) | 2008-09-12 | — | — | WO | disclosed |
| EP-1045875-A1 | HARD FOAMED PLASTIC MOULDED BODIES WITH A COMPACT OUTER SKIN | Henkel Kommanditgesellschaft auf Aktien (DE) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999032545-A1 | HARD FOAMED PLASTIC MOULDED BODIES WITH A COMPACT OUTER SKIN | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1999-07-01 | — | — | WO | disclosed |
| US-5151405-A | Multilayer element of a support and a modified dextran binder | AGFA-GEVAERT, N.V. (BE) | 1992-09-29 | — | — | US | disclosed |
| JP-S5640658-A | AROMATIC CARBAMATE CARBONATE AND ITS PREPARATION | MITSUI TOATSU CHEM INC | 1981-04-16 | — | — | JP | disclosed |
| US-3965168-A | CITRIC ACID INTERMEDIATE | ETHYL CORPORATION (US) | 1976-06-22 | — | — | US | disclosed |
| US-3960941-A | CHEMICAL INTERMEDIATE FOR CITRIC ACID | ETHYL CORPORATION (US) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328230-A1 | CLEARANCE OF AMYLOID BETA | BACE1, APP, BCHE | LMNA 1900/4885ALDH1A1 1860/4885OR51E2 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.